- Home
- SCWO vs BTAI Comparison
SCWO vs BTAI Comparison
Compare SCWO & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCWO
- BTAI
- Stock Information
- Founded
- SCWO 2021
- BTAI 2017
- Country
- SCWO United States
- BTAI United States
- Employees
- SCWO N/A
- BTAI N/A
- Industry
- SCWO Environmental Services
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- SCWO Utilities
- BTAI Health Care
- Exchange
- SCWO Nasdaq
- BTAI Nasdaq
- Market Cap
- SCWO 49.2M
- BTAI 52.7M
- IPO Year
- SCWO N/A
- BTAI 2018
- Fundamental
- Price
- SCWO $0.37
- BTAI $2.48
- Analyst Decision
- SCWO
- BTAI Buy
- Analyst Count
- SCWO 0
- BTAI 5
- Target Price
- SCWO N/A
- BTAI $32.80
- AVG Volume (30 Days)
- SCWO 813.3K
- BTAI 1.6M
- Earning Date
- SCWO 11-12-2025
- BTAI 11-13-2025
- Dividend Yield
- SCWO N/A
- BTAI N/A
- EPS Growth
- SCWO N/A
- BTAI N/A
- EPS
- SCWO N/A
- BTAI N/A
- Revenue
- SCWO $1,231,413.00
- BTAI $868,000.00
- Revenue This Year
- SCWO $5,945.19
- BTAI N/A
- Revenue Next Year
- SCWO $106.82
- BTAI $614.78
- P/E Ratio
- SCWO N/A
- BTAI N/A
- Revenue Growth
- SCWO 403.17
- BTAI N/A
- 52 Week Low
- SCWO $0.16
- BTAI $1.17
- 52 Week High
- SCWO $1.95
- BTAI $13.28
- Technical
- Relative Strength Index (RSI)
- SCWO 65.88
- BTAI 38.09
- Support Level
- SCWO $0.28
- BTAI $2.47
- Resistance Level
- SCWO $0.32
- BTAI $2.70
- Average True Range (ATR)
- SCWO 0.03
- BTAI 0.21
- MACD
- SCWO 0.00
- BTAI -0.00
- Stochastic Oscillator
- SCWO 83.14
- BTAI 9.74
About SCWO 374Water Inc.
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.